New study tracks Elacestrant's Real-World impact on advanced breast cancer
NCT ID NCT07563595
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 500 postmenopausal women with advanced ER+ HER2- breast cancer that has an ESR1 mutation. Participants receive elacestrant as part of their normal care. Researchers will track quality of life, side effects, and how the cancer responds over time. The goal is to understand how well this drug works outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elacestrant (Orserdu®)
What this could lead to
If successful, this study could provide real-world evidence on how well elacestrant controls advanced breast cancer and improves quality of life for patients with ESR1 mutations.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment but gathers data on existing use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gemeinschaftspraxis für Hämatologie und Onkologie
RECRUITINGRavensburg, 88212, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Praxis für interdisziplinäre Onkologie & Hämatologie
RECRUITINGFreiburg im Breisgau, 79110, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Louise Frauen- und Kinderklinik
RECRUITINGPaderborn, 33098, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••